13F-HR filed by Sarissa Capital Management LP
Sarissa Capital Management LP filed this 13F-HR for the quarter ended 2015-09-30, filed 2015-11-16, with 18 holding rows worth $404,891,000.
- Accession
- 0001140361-15-041780
- Filer
- CIK 1577524
- Filed
- 2015-11-16
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q3 2015
A holdings report, 18 entries on the cover page, a total value of $404,891,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $404,891,000 with VALUE read as thousands by filing date, 13F file number 028-15935. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| AbbVie,Inc. | 00287Y109 | COM | 1,580,000 | $85,968,000 | thousands by filing date | |
| ARIAD PHARMACEUTICALS INC | 04033A100 | COM | 12,850,000 | $75,044,000 | thousands by filing date | |
| MEDICINES CO | 584688105 | COM | 1,567,000 | $59,483,000 | thousands by filing date | |
| QUEST DIAGNOSTICS INC COM | 74834L100 | Stock | 575,000 | $35,345,000 | thousands by filing date | |
| AEGERION PHARMACEUTICALS INC | 00767E102 | COM | 2,555,000 | $34,748,000 | thousands by filing date | |
| INTRA-CELLULAR THERAPIES INC | 46116X101 | COMMON STOCK | 640,000 | $25,626,000 | thousands by filing date | |
| Merck & Co.,Inc. | 58933Y105 | COM | 400,000 | $19,756,000 | thousands by filing date | |
| PACIRA BIOSCIENCES INC COM | 695127100 | Stock | 380,000 | $15,618,000 | thousands by filing date | |
| Amgen Inc. | 031162100 | COM | 90,000 | $12,449,000 | thousands by filing date | |
| ESPERION THERAPEUTICS INC NEW COM | 29664W105 | Stock | 448,000 | $10,568,000 | thousands by filing date | |
| APRICUS BIOSCIENCES INC | 03832V109 | COM | 6,524,505 | $9,526,000 | thousands by filing date | |
| REPROS THERAPEUTICS INC | 76028H209 | COM | 1,132,367 | $8,413,000 | thousands by filing date | |
| VIVUS INC | 928551100 | COM | 2,573,943 | $4,221,000 | thousands by filing date | |
| KINDRED BIOSCIENCES INC COM | 494577109 | Stock | 689,091 | $3,583,000 | thousands by filing date | |
| AVEO PHARMACEUTICALS INC | 053588109 | COM | 2,313,759 | $2,800,000 | thousands by filing date | |
| ANI PHARMACEUTICALS INC | 00182C103 | COM | 31,000 | $1,225,000 | thousands by filing date | |
| CATALYST | 14888D109 | COM | 90,000 | $419,000 | thousands by filing date | |
| SESEN BIO, INC. | 286221106 | COM | 41,200 | $99,000 | thousands by filing date |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001140361-15-041780 | this filing | 2015-11-16 | acceptance time not in the bulk data set |